Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy is available in the UK through two routes: the NHS, where eligibility is tightly phased and waiting lists can be long, or a private prescription, where you pay out of pocket but can typically start within days. Understanding both routes — and what private pricing actually includes — is the clearest way to work out whether Wegovy fits your budget. Wegovy (semaglutide) is a prescription-only medicine, so a prescriber must assess your suitability before any supply is made.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The NHS does fund Wegovy (semaglutide 2.4mg), but access is routed through specialist weight management services and is governed by NICE's appraisal TA875, which limits it to adults with a BMI of 35 or above (or 30–34.9 in certain circumstances) alongside at least one weight-related condition, and only within a multidisciplinary programme for a maximum of two years. Ethnic-background adjustments lower the threshold by 2.5 kg/m² for some groups.
In practice, that means two hurdles: you need to meet the clinical criteria, and you need to be referred into a service that is actively accepting patients. Waiting lists in many areas stretch to months or longer. If you fall just outside the threshold, or your GP's practice hasn't yet joined the new prescribing arrangement, NHS Wegovy may simply not be accessible right now.
For people who don't meet NHS criteria or don't want to wait, a private prescription is the practical alternative. Our Wegovy overview explains the full licensed indication if you want to check where you stand before starting a consultation.
Private Wegovy pricing varies between providers and by dose. Since Eli Lilly's list-price increase for tirzepatide in September 2025 reshaped the whole market, reported private prices for semaglutide-based treatment have typically ranged roughly £149–£375 per month depending on the dose pen and the provider, though those figures shift, so treat them as context rather than a quote.
The more important question is what any quoted price actually covers. Some providers charge separately for the consultation, the prescription, delivery and any follow-up clinical support. Others roll everything in. When you're comparing costs, a lower headline number that excludes clinical review and aftercare isn't necessarily cheaper once you add those up. You can read more about how private treatment pricing works on our page on getting a Wegovy prescription in the UK.
At nume, one price covers the consultation, the prescription, the treatment, and free next-working-day tracked delivery, no separate fees, no subscription that auto-renews. We're not positioned as the lowest-cost option; we're positioned as the most complete one. If you want to see current treatment pricing, it's all on the treatment page.
This is the question our prescribers hear regularly, and the honest answer is: not really, not safely. Wegovy is a prescription-only medicine. That legal classification exists because semaglutide has real contraindications, real interactions, and real side effects, the NHS semaglutide medicines page covers them clearly. Clinical oversight isn't a box-ticking step you can cut to save money; it's the part that keeps the treatment appropriate for you specifically.
Discount codes for prescription weight-loss medicines from sellers you can't verify on the GPhC pharmacy register are a genuine safety risk. The MHRA has seized large quantities of fake weight-loss pens sold online, some containing insulin rather than the labelled medicine. A counterfeit pen isn't cheap; it's dangerous.
The one legitimate cost consideration is timing. Starting treatment earlier in the month, keeping your pen in the fridge door as a visible daily reminder to use it consistently, and attending your clinical reviews means you're less likely to repeat a dose or lose a pen to improper storage, and our guide to doing your Wegovy shot correctly covers the technique that helps you get the most from every dose. Getting value from the treatment you're paying for is the only real saving available. Our guide to starting Wegovy covers the practical side of making treatment work from day one.
That's a fair thing to sit with. Weight management treatment is a medium-to-long-term commitment, and starting when you can't sustain the cost isn't ideal for anyone. A few things worth knowing before you decide.
First, Wegovy isn't the only licensed option. If you're weighing up semaglutide against tirzepatide, our semaglutide page and the weight-loss treatments overview both lay out the differences without pushing you toward one or the other. Second, some people do move between private and NHS treatment as their circumstances change, understanding what stopping looks like is worth reading before you commit; see our piece on stopping Wegovy for what the evidence says about weight after discontinuation.
Third, if cost is the main barrier and you do meet the NHS criteria, a GP referral is free and worth pursuing even if the wait is frustrating. Our FAQs cover the most common questions about both routes.
If you'd like a human view on your situation rather than a self-assessment quiz, speak to our prescribers through a free consultation, there's no obligation, and the review happens the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.